A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems

Inclusion Criteria : * Adult participants ≥18 years and ≤80 years of age at Visit 1. * Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to participation in the trial. * Male and female participants. Women of childbearing potential must be willing and able to use a highly effective method of contraception per ICH M3 (R2) that results in a low failure rate (i.e. \<1% per year when used consistently and correctly) for the duration of the trial until at least 14 days after drug administration. Throughout the trial and for a period of at least 14 days after investigational medicinal product (IMP) administration, male participants with sexual partners who are women of child-bearing potential must use condoms or practice complete abstinence. * Body mass index (BMI) of 18.5-42.0 kg/m² (inclusive) at Visit 1. Inclusion criteria Cohort 4 (participants with normal hepatic function) \- Clinically healthy based on medical history, physical examination, vital signs, Electrocardiogram (ECG), and laboratory tests at Visit 1. Inclusion criteria Cohorts 1, 2 and 3 (participants with hepatic impairment) * Hepatic impairment that meets the criteria for Child-Pugh classes A (Cohort 1), B (Cohort 2), or C (Cohort 3). * Hepatic decompensation therapies (e.g., diuretics for ascites, lactulose for hepatic encephalopathy, nonselective betablockers for portal hypertension) need to compl…